A5062641058- Acute Myeloid Leukemia Research
- Chronic Myeloid Leukemia Treatments
- Chronic Lymphocytic Leukemia Research
- Acute Lymphoblastic Leukemia research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Histone Deacetylase Inhibitors Research
- Multiple Myeloma Research and Treatments
- Lung Cancer Treatments and Mutations
- Eosinophilic Disorders and Syndromes
- PI3K/AKT/mTOR signaling in cancer
- Neutropenia and Cancer Infections
- CAR-T cell therapy research
- Adenosine and Purinergic Signaling
- Ubiquitin and proteasome pathways
- Cytokine Signaling Pathways and Interactions
- Retinoids in leukemia and cellular processes
- Lymphoma Diagnosis and Treatment
- Autoimmune Bullous Skin Diseases
- Complement system in diseases
- Immunodeficiency and Autoimmune Disorders
- Mast cells and histamine
- Glioma Diagnosis and Treatment
- Vascular Tumors and Angiosarcomas
- Redox biology and oxidative stress
- Powdery Mildew Fungal Diseases
Instytut Hematologii i Transfuzjologi
2016-2025
Institute of Haematology and Blood Transfusion
2025
Medical University of Warsaw
2023
Postgraduate School of Molecular Medicine
2014-2019
Instituto de Biomedicina de Sevilla
2019
Treatment results for patients with newly diagnosed FMS-like tyrosine kinase 3 (FLT3)-mutated (FLT3mut+) acute myeloid leukemia (AML) ineligible intensive chemotherapy are disappointing. This multicenter, open-label, phase trial randomized (2:1) untreated adults FLT3mut+ AML induction to receive gilteritinib (120 mg/d orally) and azacitidine (GIL + AZA) or (AZA) alone. The primary end point was overall survival (OS). At the interim analysis (August 26, 2020), a total of 123 were treatment...
Abstract Blast phase (BP) of chronic myeloid leukemia (CML) still represents an unmet clinical need with a dismal prognosis. Due to the rarity condition and heterogeneity biology presentation, prospective trials concise treatment recommendations are lacking. Here we present analysis European LeukemiaNet Phase Registry, international collection outcome blast phases which had been diagnosed in CML patients after 2015. Data reveal expected entity, lacking clear standard. Outcomes remain dismal,...
Background: Quizartinib (Quiz) is an oral, highly potent, and selective type II FLT3 inhibitor with single-agent activity in relapsed/refractory FLT3–internal tandem duplication positive (FLT3-ITD+) acute myeloid leukemia (AML). This the first report of global, randomized, double-blind, placebo (PBO)-controlled phase 3 QuANTUM-First trial (NCT02668653). Aims: aimed to determine if addition Quiz standard induction (IND) post remission (including allogeneic hematopoietic cell transplant...
Guadecitabine is a novel hypomethylating agent (HMA) resistant to deamination by cytidine deaminase. Patients with relapsed/refractory acute myeloid leukemia (AML) were randomly assigned guadecitabine or preselected treatment choice (TC) of high-intensity chemotherapy, low-intensity HMAs low-dose cytarabine, best supportive care (BSC). The primary end point was overall survival (OS). A total 302 patients (n = 148) TC 154). Preselected TCs 233 [77%; mainly HMAs]), chemotherapy 63 [21%]), and...
B‐cell precursor acute lymphoblastic leukemia (BCP‐ALL) is a genetically heterogeneous blood cancer characterized by abnormal expansion of immature B cells. Although intensive chemotherapy provides high cure rates in majority patients, subtypes harboring certain genetic lesions, such as MLL rearrangements or BCR‐ABL1 fusion, remain clinically challenging, necessitating search for other therapeutic approaches. Herein, we aimed to validate antioxidant enzymes the thioredoxin system potential...
Abstract Spleen tyrosine kinase (SYK) is an important oncogene and signaling mediator activated by cell surface receptors crucial for acute myeloid leukemia (AML) maintenance progression. Genetic or pharmacologic inhibition of SYK in AML cells leads to increased differentiation, reduced proliferation, cellular apoptosis. Herein, we addressed the consequences stem-cell (LSC) function assessed SYK-associated pathways biology. Using gain-of-function MEK mutant constitutively active STAT5A,...
QuANTUM-First (NCT02668653) was a randomized phase 3 trial in newly diagnosed FLT3-ITDQpositive acute myeloid leukemia (AML) patients treated with quizartinib or placebo plus standard induction and consolidation chemotherapy and/or allogeneic hematopoietic cell transplantation (allo-HCT), followed by single-agent maintenance therapy. We evaluated the impact of allo-HCT performed first complete remission (CR1) composite CR1 (CRc1) on overall survival (OS), considering treatment randomization....
Abstract The prognosis for B-cell precursor acute lymphoblastic leukemia patients with Mixed-Lineage Leukemia ( MLL ) gene rearrangements (MLLr BCP-ALL) is still extremely poor. Inhibition of anti-apoptotic protein BCL-2 venetoclax emerged as a promising strategy this subtype BCP-ALL, however, lack sufficient responses in preclinical models and the possibility developing resistance exclude using monotherapy. Herein, we aimed to uncover potential mechanisms responsible limited activity MLLr...
This prospective study estimated outcomes in 509 elderly patients with acute myeloid leukemia (AML) different treatment approaches depending on Eastern Cooperative Oncology Group (ECOG) performance status and Charlson Comorbidity Index (CCI). Patients were stratified into fit (ECOG 0-2 CCI 0-2) or frail (ECOG>2 and/or CCI>2) groups. Fit 0 received intensive chemotherapy whilst reduced-intensive (R-IC) was given to those 1-2. Frail best supportive therapy. presented a longer overall survival...
Acute myeloid leukemia (AML) in older unfit patients is a therapeutic challenge for clinical hematologists. We evaluated the efficacy and safety of novel low-intensity regimen consisting low-dose cytarabine cladribine (LD-AC+cladribine) first-line treatment elderly (≥60 years) AML not eligible intensive chemotherapy (IC) who had either Eastern Cooperative Oncology Group performance status (ECOG PS) ≥2 or hematopoietic cell transplantation comorbidity index (HCT-CI) score ≥3. The induction...
Introduction: Central Nervous System involvement (CNSi) in patients with Acute Myeloid Leukemia (AML) rarely occurs. It is not well characterized clinically and lacks standardized treatments. Patients methods: A retrospective analysis of 77 consecutive AML primary secondary CNSi during 2004-2016 was performed eight Polish haematological centres. Results: (38 CNSi-AML) were included. Median age 44 years both groups. Elevated lactate dehydrogenase activity found the majority subjects. CNSi-AML...
Chimeric antigen receptor (CAR) T-cell therapy has had considerable success in the treatment of B-cell malignancies. Targeting B-lineage marker CD19 brought great advances to acute lymphoblastic leukemia and lymphomas. However, relapse remains an issue many cases. Such can result from downregulation or loss malignant cell population expression alternate isoforms. Consequently, there a need target alternative antigens diversify spectrum epitopes targeted within same antigen. CD22 been...
Lenalidomide has been approved for the treatment of lower-risk myelodysplastic syndrome (MDS) with 5q deletion (del(5q)). We present first time a retrospective analysis low-risk MDS isolated del5q treated lenalidomide, outside clinical trials. 36 red blood cell (RBC) transfusion-dependent patients have included in study. Patients received lenalidomide 10 mg/day on days 1–21 28-day cycles. 91.7 % responded to treatment: 72.2 achieved erythroid response, 19.4 minor response and 8.4 did not...
Tyrosine kinase inhibitors (TKIs) have greatly improved the treatment outcome for most patients with chronic myeloid leukemia (CML). Ponatinib is a new pan-inhibitor of TK active in resistant CML. This study aimed to evaluate efficacy and safety ponatinib suffering from CML.This multicenter, non-randomized, observational, retrospective evaluated administered adult CML any disease phase, including those detected ABL T315I mutation, which were or intolerant previous-generation TKIs. The...